

PRESS RELEASE

Cordlife Group Received Accreditation from College of American Pathologists for its Hong Kong and India Subsidiaries

- Cordlife Group's majority owned subsidiaries, Hong Kong Screening Centre Limited and Cordlife Sciences (India) Pvt. Ltd. achieved accreditation from the College of American Pathologists.
- CAP accreditation is the gold standard for laboratory management and processes, which focuses on key areas such as reliability, correctness and quality care.
- Hong Kong Screening Centre Limited is a clinical laboratory specialising in timely and accurate detection of more than 100 metabolic disorders from urine specimens of newborns.
- Cordlife Sciences (India) Pvt. Ltd. operates India's one of the most advanced umbilical cord and cord blood processing, testing and cryopreservation facilities, which is also accredited by AABB.

23 November 2016 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), Asia’s leading cord blood and cord lining banking service provider, is pleased to announce that its majority owned Hong Kong and India subsidiaries, Hong Kong Screening Centre Limited (“HKSC”) and Cordlife Sciences (India) Pvt. Ltd. (“Cordlife India”), consecutively received accreditation from the College of American Pathologists (“CAP”). This accreditation is awarded to facilities that meet or exceed the highest standards in laboratory services.

HKSC is a Hong Kong-based clinical laboratory specialising in timely and accurate detection of over 100 metabolic disorders from urine specimen. This comprehensive non-invasive newborn screening service is currently marketed through Cordlife subsidiaries in Hong Kong, Indonesia and Philippines. Cordlife India operates India's one of the most advanced umbilical cord and cord blood processing, testing and cryopreservation facilities, which is also accredited by the American Association of Blood Banks (“AABB”).

The CAP accreditation program focuses on four key areas which include reliability, correctness, quality care, lab management and safety. The accreditation is awarded to facilities after a rigorous on-site inspection as well as examination of the facility's records and quality management system for the past two years.

Ms Tan Poh Lan, Group Chief Operating Officer of Cordlife said: "Receiving CAP accreditation for both our facilities in Hong Kong and India at the same time is a solid validation of our quality management system and competence. This reaffirms Cordlife's commitment and belief in providing the highest quality of healthcare services to our clients regardless of where we operate."

- The End -

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a consumer healthcare company catering to the mother and child segment and a leading cord blood and umbilical cord lining banking services provider.

Today, Cordlife has the largest¹ market share of private cord blood banks in Singapore, Philippines and Indonesia; and is amongst the top three market leaders in Hong Kong and India. In December 2015, Cordlife increased its shareholding in the largest cord blood bank operator in Malaysia, Stemlife to 89.88%, making it the latest addition to the subsidiaries of the Group in the region.

Cordlife's cord blood and cord tissue processing and cryopreservation facility in Singapore is one of the only six cord blood banks in the world to be dually accredited by AABB and Fact-Netcord, two of the world's gold standard for cord blood banking. Cordlife Group is listed on the mainboard of Singapore Exchange since March 2012.

¹ Source : Deloitte & Touche Financial Advisory Services Limited report, 10 April 2013

As part of its vertical growth plan to offer complementary products and services that cater to the mother and child segment, Cordlife has expanded into more diagnostics service offerings. These include Metascreen that offers comprehensive metabolic screening test designed for newborn babies; Non-Invasive Prenatal Testing that can analyse fetal DNA in a mother's blood to screen for fetal chromosomal abnormalities.

For more information on CGL, visit <http://cordlife.listedcompany.com/>

ABOUT HONG KONG SCREENING CENTRE LIMITED

Hong Kong Screening Centre Limited ("HKSC" or the "Company") is 67% held by Cordlife's wholly-owned Hong Kong-based Cordlife Stem Cell Technology Limited. Accredited by the College of American Pathologists (CAP) Laboratory Accreditation Program, HKSC is a company committed to provide early and accurate detection of inherited metabolic disorders in newborn babies through non-invasive urine based testing. The Company adopts U.S. FDA approved gas chromatography mass spectrometry (GC/MS) equipment coupled with their in-house Planar Bioinformatics Tool for the screening of more than 100 metabolic disorders to provide accurate and more definitive results.

ABOUT CORDLIFE SCIENCES (INDIA) PVT. LTD.

Cordlife Sciences (India) Pvt. Ltd. ("Cordlife India") is a majority owned subsidiary of Cordlife Group Limited. The Company is AABB accredited and operates one of the most advanced umbilical cord and cord blood processing, testing and cryopreservation facilities in the country, with a storage capacity of 150,000 cord blood units scalable by another few lakh units. The state-of-the-art laboratory is equipped with the latest and the most modern equipment such as Swiss-made SEPAX® 2, a fully automated stem cell processing technology, in a clean-room infrastructure to ensure that stem cells are processed under the most sterile conditions. Located within a natural calamity proof building, the facility is also built with continuous power backup and round-the-clock surveillance system. The Company operates more than 50 centers in India, making it one of the largest stem cell banking companies locally. In 2011, Cordlife India successfully released a stem cell unit for the first ever mixed stem cell transplant in India.



ISSUED ON BEHALF OF : Cordlife Group Limited
BY : Financial PR Pte Ltd
4 Robinson Road #04-01
The House of Eden
Singapore 048543
CONTACT : Mr Kamal Samuel / Mr Ngo Yit Sung/ Ms Sheryl Sim
OFFICE : 6438-2990
EMAIL : cordlife@financialpr.com.sg
